All In Biotech

Drug Trial Radar · NCT04303039

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

A Phase I Study to Investigate the Effects of Food on the Relative Bioavailability of a Tablet Formulation of ABP-671 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jun 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

May 22, 2020

Primary completion

Jun 9, 2020

Study completion Jun 19, 2020

Sponsor

Lead sponsor
Atom Therapeutics Co., LtdIndustry
Sponsor type
Industry
First posted
Mar 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single center, open-label, single-dose, 2-way randomized crossover design in which 12 healthy subjects will be randomized to 1 of 2 treatment sequences (AB or BA). Treatments A and B will consist of single oral dose of tablet formulation (1.0 mg as 1 x 1.0 mg) in the fasted and fed state administered with approximately 240 mL of water. Each period will be separated by a washout interval of 4 days.

Conditions

  • Gout
  • Food-drug Interaction

Interventions

  • ABP-671Drug

    ABP-671 Tablet 1.0 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma ABP-671 ConcentrationTime frame: 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron CPC, Inc.

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.